Skip to main content

Moxalactam therapy for obstetric and gynecologic infections.

Publication ,  Journal Article
Gall, SA; Addison, WA; Hill, GB
Published in: Rev Infect Dis
1982

Moxalactam, a new cephalosporin antibiotic with a broad spectrum of activity, was evaluated for safety and therapeutic efficacy in the treatment of genital tract infections in women. Fifty-three patients with postpartum endometritis or acute or chronic pelvic inflammatory disease were treated with 2 g of moxalactam iv every 8 hr, usually for five days or longer. Appropriate cultures of peripheral blood, endometrium, cul-de-sac aspirates, urine, wound, and endocervix (only for Neisseria gonorrhoeae) were performed. Overall, 90.6% (48 of 53) of the patients were successfully treated with moxalactam--86.2% (25 of 29) and 95.8% (23 of 24) of the patients with endometritis and pelvic inflammatory disease, respectively. Therapy failed in one of five bacteremic patients with endometritis. Of all the bacteria isolated from appropriate culture sites, 58% (224 of 383) were anaerobes, with anaerobic gram-negative rods--particularly Bacteroides bivius-and gram-positive cocci being predominant. Of 206 anaerobic strains tested with moxalactam by agar dilution techniques, 82% (169 of 206) were susceptible (minimal inhibitory concentration [MIC], less than or equal to 8 micrograms/ml), 11.6% (24 of 206) were moderately susceptible (MIC, 16-32 micrograms/ml), and 6.3% (13 of 206) were resistant (MIC, greater than or equal to 64 micrograms/ml). Among the aerobic isolates, enterococci were uniformly resistant. Thus, moxalactam performed well as a single agent in this open clinical trial for women with infections of the genital tract.

Duke Scholars

Published In

Rev Infect Dis

DOI

ISSN

0162-0886

Publication Date

1982

Volume

4 Suppl

Start / End Page

S701 / S707

Location

United States

Related Subject Headings

  • Pregnancy Complications, Infectious
  • Pregnancy
  • Moxalactam
  • Humans
  • Genital Diseases, Female
  • Female
  • Cephamycins
  • Cephalosporins
  • Anaerobiosis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gall, S. A., Addison, W. A., & Hill, G. B. (1982). Moxalactam therapy for obstetric and gynecologic infections. Rev Infect Dis, 4 Suppl, S701–S707. https://doi.org/10.1093/clinids/4.supplement_3.s701
Gall, S. A., W. A. Addison, and G. B. Hill. “Moxalactam therapy for obstetric and gynecologic infections.Rev Infect Dis 4 Suppl (1982): S701–7. https://doi.org/10.1093/clinids/4.supplement_3.s701.
Gall SA, Addison WA, Hill GB. Moxalactam therapy for obstetric and gynecologic infections. Rev Infect Dis. 1982;4 Suppl:S701–7.
Gall, S. A., et al. “Moxalactam therapy for obstetric and gynecologic infections.Rev Infect Dis, vol. 4 Suppl, 1982, pp. S701–07. Pubmed, doi:10.1093/clinids/4.supplement_3.s701.
Gall SA, Addison WA, Hill GB. Moxalactam therapy for obstetric and gynecologic infections. Rev Infect Dis. 1982;4 Suppl:S701–S707.

Published In

Rev Infect Dis

DOI

ISSN

0162-0886

Publication Date

1982

Volume

4 Suppl

Start / End Page

S701 / S707

Location

United States

Related Subject Headings

  • Pregnancy Complications, Infectious
  • Pregnancy
  • Moxalactam
  • Humans
  • Genital Diseases, Female
  • Female
  • Cephamycins
  • Cephalosporins
  • Anaerobiosis